Navigation Links
Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
Date:12/16/2008

EMERYVILLE, Calif., Dec. 16 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) (NTI(R)) today announced that Celtic Pharmaceutical Holdings L.P. (Celtic) has provided an update on XERECEPT(R).

NTI sold the worldwide rights and assets related to XERECEPT to Celtic in November 2005. NTI is entitled to receive milestone payments upon the achievement of certain regulatory approvals, and if XERECEPT is approved for commercial sale, NTI is also entitled to receive profit-sharing payments on sales in the United States and royalties on sales elsewhere in the world.

"We are very pleased at the effort Celtic has applied to this project, bringing it to the point of producing, understanding and presenting solid clinical data to the medical community while simultaneously undertaking a preclinical program to expand the future potential applications of XERECEPT," said Paul E. Freiman, president and chief executive officer. "Further, our partnership has flourished on a personal basis and we both feel each party has added value to the collaboration."

    The text of the press release from Celtic is as follows:

       "Celtic Pharma Announces Update on Status of XERECEPT(R) Program
                            Sale Planned in 2009"

     "New York, London and Bermuda, December 16, 2008 - Celtic Pharmaceutical
     Holdings L.P. ("Celtic Pharma")announced today that the databases have
     been locked and preliminary analyses completed on the two double-blinded
     studies of XERECEPT(R) (corticorelin acetate), as a treatment for
     peritumoral brain edema, as well as an initial database lock on the
     open-label study of XERECEPT's long-term safety and efficacy.

     "The results of these studies are the subject of several abstract
     submissions for the American Society of Clinical Oncolo
'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
2. Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
3. Neurobiological Technologies Sets Date for First Quarter Financial Results
4. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
5. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
6. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
7. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
8. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
9. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
10. Neurobiological Technologies CEO to Retire on December 31, 2008
11. Neurobiological Technologies Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 Spartan Bioscience announced today ... CYP2C19 System . It detects CYP2C19 genetic mutations in ... , The Spartan RX CYP2C19 System is the first ... approved in Canada. Due to the system’s ease of ... used by healthcare professionals such as doctors, nurses, pharmacists, ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success and ... its fleet of high volume High Pressure Processing (HPP) systems. ... return to PackExpo this year, which is where we first ... Jeff Williams, CEO at Avure. “Sales of the new Avure ... meeting the challenges of market demand for higher throughput. We ...
(Date:10/30/2014)... 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... will present a company overview at the Nomura Biotechnology Conference ... Boston, MA. A live ... & Media" section of the Company,s website, www.isispharm.com .  ... 48 hours and will be archived for a limited time. ...
(Date:10/30/2014)...  Regado Biosciences, Inc. (Nasdaq: RGDO ), ... and live audio webcast on Thursday, November 6, 2014, ... 2014 financial results. Interested participants and investors ... for domestic callers or (412) 902-4276 for international callers. ... investor relations section of the Regado website at ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2
... siRNA expression construct into a variety of mammalian cells ... , ... Modified CMV promoter efficiently expresses hairpin siRNAs , ... , Efficient delivery of siRNA or an siRNA , ...
... In the past few years, interest in the , ... small RNA molecules has , ... interrelated lines of research. In one, small double-stranded , ... (siRNAs) have been , ...
... Dicer and Escherichia coli RNase III can be used ... cleave long dsRNA, producing siRNA cocktails that are , ... endoribonuclease that contains RNase III domains and is the , ... of long dsRNAs to siRNA in the , ...
Cached Biology Technology:Delivering siRNA Using Adenoviral Vectors 2Delivering siRNA Using Adenoviral Vectors 3Delivering siRNA Using Adenoviral Vectors 4Detecting miRNA & siRNA 2Detecting miRNA & siRNA 3Detecting miRNA & siRNA 4Detecting miRNA & siRNA 5Detecting miRNA & siRNA 6Detecting miRNA & siRNA 7Detecting miRNA & siRNA 8Detecting miRNA & siRNA 9Dicer vs. RNase III for Preparation of siRNA Cocktails 2Dicer vs. RNase III for Preparation of siRNA Cocktails 3
(Date:10/29/2014)... food, but they also need protection from its harmful rays, ... molecules in plants that shields them from sun damage. Now, ... Chemical Society , one team reports on the mechanics of ... colleagues at Purdue University note that the harsh ultraviolet radiation ... plant DNA and, as a result, hinder plant growth. ...
(Date:10/29/2014)... nanoparticles is all the rage. Thousands of scientists worldwide ... of whether titanium dioxide nanoparticles from sun creams can ... carbon nanotubes from electronic products are as hazardous for ... nanoparticles in food can get into the blood via ... research funds are flowing – and the number of ...
(Date:10/29/2014)... – As bodies decompose, their types and numbers ... they provide could mean the difference between a ... State University is using a more than $866,000 ... death-scene investigators examine these changing populations. The microbial ... location of death, gender, race, socioeconomic relations and ...
Breaking Biology News(10 mins):Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3MSU partners with Detroit to investigate death scenes 2
... 2010 - Novocure reported today that patients with advanced ... in survival time when tumor treating fields (TTF) therapy ... outcomes for patients receiving chemotherapy alone. Dr. Miklos Pless, ... center in Switzerland, presented the data at the European ...
... have reported direct evidence that taking up smoking results in ... results were reported at the 35th Congress of the European ... link between smoking and cancer has been established for decades, ... Institute of Cancer Studies, Birmingham, who presented the results. Smoking ...
... at Chicago College of Medicine have found how gene expression ... unusual types of breast tumors. Their findings may offer new ... 8 issue of the Journal of Biological Chemistry, ... Approximately 70 percent of breast cancers express the estrogen receptor. ...
Cached Biology News:Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer 2Study reveals cancer-linked epigenetic effects of smoking 2Clue to unusual drug-resistant breast cancers found 2
... Signet offers the most comprehensive, cost-effective ... We have incorporated unprecedented quality into ... This includes proven detection chemistries and ... the TechMate protocol. It also includes ...
... Detection System combines the indirect labeling ... and Signets unique formulation of ultra ... reliablility. Signet reagents will achieve excellent ... automated protocols. ,Signets USA Detection reagents ...
... Level 2 Detection System combines the ... bonding principle and Signets unique formulation ... specificity and reliablility. Signet reagents will ... manual and automated protocols. ,Signets ...
Each bottle contains: Bromophenol Blue 0.25% w/v , Xylene Cyanol FF 0.25%, Glycerol solution 30% w/v...
Biology Products: